Apter v. Department of Health and Human Services, No. 22-40802 (5th Cir. Sept. 1, 2023) (2023)

Government Record · U.S. Court of Appeals for the Fifth Circuit (Willett, J.) · September 1, 2023

U.S. Court of Appeals for the Fifth Circuit (Willett, 2023-09-01: The Fifth Circuit held that three doctors could sue FDA over its public statements discouraging ivermectin use, reviving an APA challenge; the opinion concerns ivermectin, not fenbendazole.

“You are not a horse.” Or so the Food and Drug Administration (“FDA”) alerted millions of Americans via social media, midway through the COVID-19 pandemic. The agency had discerned that some people were treating their symptoms using the animal version of a drug called ivermectin.

1

U.S. Court of Appeals for the Fifth Circuit (Willett, 2023-09-01: The Fifth Circuit held that three doctors could sue FDA over its public statements discouraging ivermectin use, reviving an APA challenge; the opinion concerns ivermectin, not fenbendazole. F5. HOST (court PDF). The case concerns FDA's 'horse' messaging about ivermectin; plaintiffs Robert L. Apter, Mary Talley Bowden and Paul E. Marik. It does not mention fenbendazole. No 'Cancer Research Advocacy Network' was located (web search returns nothing under that name), and no lawsuit over fenbendazole access was found; the only fenbendazole-adjacent proceeding located is Makis's Alberta case described in his own Substack post (FBA-30). Recorded so the F5 verdict rests on a real court document rather than on absence alone. Study type: other.